News

Two Accepted Abstracts at AACR 2024 Explore Clinical Applications of TK1 Biomarker

Mar 11, 2024

We are happy to announce that two abstracts on clinical applications of AroCell TK 210 ELISA have been accepted for poster presentations at the American Association of Cancer Research 2024 (AACR 2024) held from April 5 to 10 in San Diego, USA.

One of the abstracts is on the prognostic value of serum TK1 protein levels in Diffuse large B cell lymphoma (DLBCL) patients treated with a combination therapy called R-CHOP.
Below is the link for the full abstract:
https://www.abstractsonline.com/pp8/#!/20272/presentation/1871
 
The other abstract is on serum TK1 protein concentrations as a predictive marker for castration resistance in metastatic prostate cancer.
Below is the link for the abstract:
https://www.abstractsonline.com/pp8/#!/20272/presentation/11593

Strategy update: IDL Diagnostics

Nov 28, 2025 | , ,

A strategy update with IDL Diagnostics was held on November 27th at Redeye, where CEO Anders Hultman and the management team presented recent achievements, spotlighted key initiatives, and discussed future opportunities looking toward 2026 and beyond. After their...

read more

Thesis projects at IDL Diagnostics.

Jun 10, 2025 | ,

We are pleased to recognize four outstanding students who have recently completed their thesis projects with us at IDL Diagnostics. The projects started in January 2025. Putri Rezqita and Yu Shi from Karolinska Institutet contributed their deep knowledge in health and...

read more